Place de l’ADN tumoral circulant dans la prise en charge des cancers : entre défis et nouvelles perspectives (notice n° 681189)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04458cam a2200361 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121203213.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Toussaint, Paul |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Place de l’ADN tumoral circulant dans la prise en charge des cancers : entre défis et nouvelles perspectives |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 50 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméDepuis près de 20 ans, l’identification des mécanismes moléculaires impliqués dans la cancérogenèse et le développement de thérapies ciblées ont révolutionné la prise en charge des patients atteints de cancer. Le diagnostic moléculaire des tumeurs, permettant l’identification d’altérations moléculaires au sein du tissu tumoral, est devenu essentiel pour la prise en charge des patients atteints de cancer. Il permet notamment d’orienter le diagnostic, d’adapter la prise en charge en fonction du pronostic mais également de choisir les traitements les plus adaptés, notamment en identifiant les marqueurs de sensibilité et de résistance à certaines thérapeutiques. Cependant, les prélèvements tumoraux tissulaires nécessaires pour cette analyse représentent un geste invasif, sont parfois difficiles à réaliser et ne reflètent généralement pas l’hétérogénéité tumorale. La biopsie liquide, reposant sur l’analyse de l’ADN tumoral circulant (ctDNA) libéré dans les fluides biologiques par les cellules tumorales, est reconnue comme une alternative prometteuse à la biopsie tissulaire conventionnelle. L’amélioration des techniques d’enrichissement du ctDNA à partir des prélèvements biologiques et le recours à des techniques ultrasensibles d’analyse ont permis l’utilisation des biopsies liquides à visée théranostique en routine dans les cancers bronchiques. L’intérêt des biopsies liquides dans d’autres cancers est actuellement évalué dans de nombreuses études cliniques. D’autres applications sont aujourd’hui envisageables pour la pratique clinique : le dépistage et la détection précoce des cancers, le suivi de la maladie, la réponse au traitement et la détection de mécanismes de résistance. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Over the past 20 years, identification of the molecular mechanisms involved in carcinogenesis and the development of targeted therapies have revolutionised cancer treatment. The molecular diagnosis of tumours, leading to the identification of molecular changes within the tumour tissue, has become essential for the treatment of cancer patients. This guides diagnosis and allows treatment to be adjusted according to the prognosis, but also helps in the selection of the most appropriate treatment, in particular, by identifying markers that are sensitive or resistant to certain treatments. However, the techniques used to take tumour tissues samples for this analysis are invasive, sometimes difficult to carry out, and generally do not reflect the heterogeneity of the tumour. A liquid biopsy, based on circulating tumour DNA (ctDNA) released into biological fluids by the tumour cells, has been recognised as a promising alternative to conventional tissue biopsies. The improvement in ctDNA enrichment techniques based on biological samples and the use of ultrasensitive analytical techniques have led to the routine use of liquid biopsies for theranostic purposes in bronchial cancers. The use of liquid biopsies in other cancers is currently being assessed in numerous clinical studies. Other applications can now be envisaged in clinical practice, including screening and early diagnosis of cancers, patient follow-up, response to treatment and identifying mechanisms of resistance. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | biopsie liquide |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | PCR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | NGS |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ADN tumoral circulant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | liquid biopsy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | PCR |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | circulating tumour DNA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | NGS |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dardare, Julie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Harlé, Alexandre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lambert, Aurélien |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lévy, Julien |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Merlin, Jean-Louis |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Betz, Margaux |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Witz, Andréa |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gilson, Pauline |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 8 | 3 | 2022-05-01 | p. 147-156 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2022-3-page-147?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2022-3-page-147?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux